Examining the prevalence of prediabetes in pediatrics (VIDEO)

The FDA has approved lutetium Lu 177 dotatate for pediatric patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.

Contemporary Pediatrics sits down exclusively with Philippe F. Backeljauw, MD, a pediatric endocrinologist to discuss the one key condition for which he believes community pediatricians should be especially aware-Turner syndrome.

A qualitative analysis shows adolescents and their parents more frequently report an unreadiness to transition from pediatric to adult type 1 diabetes care.

Crinecerfont, an investigational, oral, selective corticotropin-releasing factory type 1 receptor antagonist, achieved the primary and key secondary endpoints in a phase 3 study to treat congenital adrenal hyperplasia due to 21-hydroxylase deficiency in children aged 2 to 17 years.

According to the study, maintaining modest residual beta cell function in newly diagnosed patients is associated with a lower risk of vascular complications and hypoglycemia. 

The US FDA announced the approval of teplizumab (Tzield), which is administered through IV infusion once daily for 14 consecutive days, for delaying the onset of stage 3 type 1 diabetes in adults and pediatric patients 8 years and older who currently have stage 2 type 1 diabetes.